Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

Fig. 1

Response to treatment with pembrolizumab + rivoceranib. Kaplan-Meier Curves demonstrating A Progression Free Survival as well as B Overall survival. The shaded area represents the pointwise 95% confidence interval. Representative CT images from a patient with metastatic Her2-overexpressed gastric adenocarcinoma C 12 / 27 / 2018 CT abdomen demonstrated initial progression following mFOLFOX6 while on Herceptin maintenance prior to starting second line Pembrolizumab. D Restaging imaging 4 / 9 / 2019 following cycle 4 Pembrolizumab demonstrating continued progression. E Restaging CT abdomen 7/ 1 /2019, one week prior to cycle one Pembrolizumab + Rivoceranib. F Restaging CT abdomen 9/6 /2019 demonstrating reduction in size of multiple sites of metastatic disease while on trial

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us